Sleep disruptions from tirzepatide and GLP-1 related insomnia typically resolve as the dose decreases, which is one benefit of tapering, but your sleep hygiene practices need to be solid independently
Always follow up with SPF to avoid sensitivity
In total, 25 (14.0%) participants discontinued treatment prematurely, primarily because of adverse events ( n = 8 [4.5%])
It is a GLP-1 (glucagon-like peptide-1 agonist) that works to improve glycemic control
None is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition
Most clinicians recommend starting GLP-1 first, stabilizing through the dose escalation phase, and then adding carbohydrate restriction once medication effects are predictable